PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
- Conditions
- Small Cell Lung Carcinoma
- Registration Number
- NCT06247163
- Lead Sponsor
- University Hospital, Essen
- Brief Summary
There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF
- Detailed Description
The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- Histopathologic confirmation
- Limited disease
- Other histology than small cell lung cancer
- Further tumor diagnosis
- ECOG 3 or worse
- Extensive disease
- stage IV
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Distant recurrence free survival 2 months to 5 years Distant recurrence free survival
Overall survival 2 months to 5 years Overall survival
Local recurrence free survival 2 months to 5 years Local recurrence free survival
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Essen
🇩🇪Essen, Germany